Isolation of bacteriophages against multidrug resistant Acinetobacter baumannii

Research in Pharmaceutical Sciences

Volumn 12, Issue 5, 2017, Pages 373-380

  Ghajavand, Hasan ^a   Esfahani, Bahram ^a   Havaei, Asghar ^a   Fazeli, Hossein ^a   Jafari, Reyhaneh ^b   Moghim, Sharareh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Bacteriophage; Multidrug resistant Acinetobacter baumannii; Phage therapy

Indexed keywords

AMIKACIN; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; MEROPENEM; SULTAMICILLIN; TETRACYCLINE;

ACINETOBACTER BAUMANNII; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE; CONTROLLED STUDY; HOST RANGE; MULTIDRUG RESISTANCE; MYOVIRIDAE; NONHUMAN; PHAGE THERAPY; PODOVIRIDAE; TURBIDITY; VIRUS ISOLATION; WASTE WATER;

EID: 85029491045     PISSN: 17355362     EISSN: 17359414     Source Type: Journal    
DOI: 10.4103/1735-5362.213982     Document Type: Article

References (28)

1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistunat Acinetobacter baumannii. Antimicrob Agent Chemother. 2007, 51(10):3471-3348.
2. Barbolla RE, Centron D, Maimones, Rospide F, Salgueila C, Altclas J, et al. Molecular epidemiology of Acinetobacter baumannii spread in an adult intensive care unit under an endemic setting. Am J Infect Control. 2008;36(6):444-452.
3. Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis. 1996;23(3):538-542.
4. Dijkshoorn L, Van Vianen W, Degener JE, Michel MF. Typing of Acinetobacter calcoaceticus strains isolated from hospital patients by cell envelope protein profiles. Epidemiol Infect. 1987;99:659-667.
5. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005;11:868-873.
6. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649-659.
7. McGrath S and van Sinderen D, (editors). bacteriophage: genetics and molecular biology (1st Ed.). Caister Academic Press. 2001. ISBN: 978-1-904455-14-1.
8. van Helvoor T. Bacteriological and physiological research styles in the early controversy on the nature of the bacteriophage phenomenon. Med Hist. 1992;3:243-270
9. Clark JR, March JB. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterial. TrendsBiotechnol. 2006; 24(5):212-218.
10. Forbes BA, Sahm DF, Weissfeld AS. Baily and Scott's diagnostic microbiology. 12th ed. Mosby Elsevier. Texas. 2007;pp: 334-339.
11. Turton JF, Woodford N, Glover J, Yard S, Kaufman ME, Pitt TL. Idenfication of Acinetobacter baumannii by detection of the blaoxa51 carbapenemase gene intrinsic to this species. J Clin Microbiol. 2006;44(8):2974-2976.
12. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Inter J Antimicrob Agents. 2006;27:351-353.
13. Morovat T, Bahram F, Mohammad E, Setareh S, Mehdi FM. Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran Hospitals. New Microbiologica. 2009;32:265-271.
14. Clinical laboratory standards institute (CLSI). Performance standards for antimicrobial susceptibility testing: twentieth informational supplement: M100-S20. Clinical laboratory standards institute, Wayne PA: USA. 2012.
15. Martha RJ Clokie. Bacteriophages methods and protocols, Volume 1. Isolation, characterization, and interactions. Humana Press. 2009; pp:15-55
16. Lin NT, Chiou PY, Chang KC, Chen LK, Lai MJ: Isolation and characterization of phi AB2: a novel bacteriophage of Acinetobacter baumannii. Res Microbiol. 2010;161:308-314.
17. Jin J, Li ZJ, Wang SW, Wang SM, Wang SM, et al. Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates. BMC Microbiol. 2012;12:156.
18. Haq I, Chaudhry WN, Andleeb S, Qadri I. Isolation and partial characterization of a virulent bacteriophage IHQ1 specific for Aeromonas punctata from stream water. Microb Ecol. 2012;63:954-963.
19. Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: Rediscovery and renewed assessment of potential. Trends Microbiol. 1997, 5:268-271.
20. Carlton RM. Phage therapy: Past history and future prospects. Arch Immunol Ther Exp. 1999;47:267-274.
21. Ackermann HW, Brochu G, Konjin HPE: Classification of Acinetobacter phages. Arch Virol. 1994; 135(3-4):345-354.
22. Soothill JS: Treatment of experimental infections of mice with bacteriophages. J Med Microbiol. 1992;37:258-261.
23. Chibani-Chenoufi S, Bruttin A, Dillmann ML, Brussow H. Phage-host interaction: an ecological perspective. J Bacteriol. 2004;186:3677-3886.
24. Bergogone Berezin E, Towner KJ. Acinetobacter spp, as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9(2):148-165.
25. Yang HJ, Liang L, Lin SX, Jia SR. Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter Baumanii. BMC Microbiol. 2010;10:131.
26. Yele AB, Thawal ND, Sahu PK, Chopade BA. Novel lytic bacteriophage AB7-IBB1 of Acinetobacter baumannii: isolation, characterization and its effect on biofilm. Arc Virol. 2012;157(8):1441-1450.
27. Lee CN, Tseng TT, Lin JW, Fu YC, Weng SF, Tseng YH. Lytic myophage Abp53 encodes several proteins similar to those encoded by host Acinetobacter baumanii and phage phiKO2. Appl Environ Microbiol. 2011;77(19):6755-6762.
28. Popova AV, Miakinina VP, Platonov ME, Volozhantsev NV. Molecular characterization of the multidrug-resistant Acinetobacter baumannii strains and assessment of their sensitivity to the phage AP22. Mol Gen MikrobiolVirusol. 2012;4:18-22.